FrancophonIA/ELRC3.0 huggingface dataset:
English: In patients with severe renal impairment or end-stage renal disease requiring dialysis Enurev Breezhaler should be used only if the expected benefit outweighs the potential risk since the systemic exposure to glycopyrronium may be increased in this population (see sections 4.4 and 5.2).
Croatian: U bolesnika s teškim oštećenjem bubrega ili bolešću bubrega u završnoj fazi koja zahtijeva dijalizu Enurev Breezhaler smije se koristiti samo ako očekivane koristi premašuju potencijalni rizik obzirom da se u ovoj populaciji može povećati sistemska izloženost glikopironiju (vidjeti dijelove 4.4 i 5.2).
English: Enurev Breezhaler once daily statistically significantly reduced the use of rescue medication (salbutamol) by 0.46 puffs per day (p=0.005) over 26 weeks and by 0.37 puffs per day (p=0.039) over 52 weeks, compared to placebo for the 6- and 12-month studies, respectively.
Croatian: Enurev Breezhaler jedanput na dan statistički značajno je smanjio korištenje lijeka za hitno ublažavanje simptoma (salbutamola) za 0,46 udisaja dnevno (p=0,005) tijekom 26 tjedana, odnosno za 0,37 udisaja dnevno (p=0,039) tijekom 52 tjedna, u usporedbi s placeboom za 6-mjesečno odnosno 12-mjesečno ispitivanje.
English: Enurev Breezhaler should be used with caution in patients with narrow-angle glaucoma or urinary retention.
Croatian: Enurev Breezhaler treba koristiti oprezno u bolesnika s glaukomom uskog kuta ili urinarnom retencijom.
English: Infections and infestations Nasopharyngitis1)
Croatian: Infekcije i infestacije Nazofaringitis
English: In the 6-month study, the percentage of patients experiencing a moderate or severe exacerbation was 17.5% for Enurev Breezhaler and 24.2% for placebo (Hazard ratio: 0.69, p=0.023), and in the 12-month study it was 32.8% for Enurev Breezhaler and 40.2% for placebo (Hazard ratio: 0.66, p=0.001).
Croatian: U 6-mjesečnom ispitivanju, postotak bolesnika koji su imali umjerenu ili tešku egzacerbaciju bio je 17,5% za Enurev Breezhaler i 24,2% za placebo (omjer rizika: 0,69, p=0,023), a u 12-mjesečnom ispitivanju bio je 32,8% za Enurev Breezhaler i 40,2% za placebo (omjer rizika: 0,66, p=0,001).
English: Only use the capsules with the inhaler provided in this pack (Enurev
Croatian: Koristite kapsule samo uz inhalator priložen u ovom pakiranju (Enurev Breezhaler inhalator).
English: Enurev Breezhaler also reduced dyspnoea at rest measured using the Transitional Dyspnoea Index.
Croatian: Enurev Breezhaler je također smanjio dispneju u mirovanju, mjereno korištenjem Prijelaznog indeksa dispneje.
English: If you forget to inhale a dose, take one as soon as possible.
Croatian: Ako ste zaboravili primijeniti Enurev Breezhaler Ako zaboravite inhalirati dozu, uzmite je čim bude moguće.
English: Show the pack of Enurev Breezhaler.
Croatian: Pokažite pakiranje Enurev Breezhalera.
English: The usual dose is to inhale the content of one capsule each day.
Croatian: Koliko Enurev Breezhalera primjenjivati Uobičajena doza je inhaliranje sadržaja jedne kapsule svaki dan.
English: In the 12-month study, Enurev Breezhaler produced statistically significant improvements in FEV1 compared to tiotropium in the first 4 hours after dosing on day 1 and at week 26, and numerically greater values for FEV1 in the first 4 hours after dosing than tiotropium at week 12 and week 52.
Croatian: U 12-mjesečnom ispitivanju, Enurev Breezhaler je doveo do statistički značajna poboljšanja u FEV1 u usporedbi s tiotropijem u prva 4 sata nakon doziranja prvog dana i nakon 26 tjedana, te numerički veće vrijednosti za FEV1 od tiotropija u prva 4 sata nakon doziranja nakon 12 tjedana i nakon 52 tjedna.
English: Enurev Breezhaler is a single-dose inhaler.
Croatian: Enurev Breezhaler je jednodozni inhalator.
English: • Do not use the Enurev Breezhaler capsules with any other inhaler.
Croatian: • Nemojte koristiti Enurev Breezhaler kapsule s drugim inhalatorima.
English: What Enurev Breezhaler is and what it is used for
Croatian: Što je Enurev Breezhaler i za što se koristi
English: At 12 weeks (primary endpoint), Enurev Breezhaler increased trough FEV1 by 72 ml in patients with the lowest degree of reversibility (<5%) and by 113 ml in those patients with a higher degree of reversibility at baseline (≥5%) compared to placebo (both p<0.05).
Croatian: Nakon 12 tjedana (primarna mjera ishoda), Enurev Breezhaler povećao je najniži FEV1 za 72 ml u bolesnika s najnižim stupnjem reverzibilnosti (<5%) te za 113 ml u onih bolesnika koji su imali viši stupanj reverzibilnosti na početku (≥5%) u usporedbi s placebom (oba p<0,05).
English: • One Seebri Breezhaler inhaler
Croatian: • Jedan Enurev Breezhaler inhalator
English: In the 6-month study, Enurev Breezhaler increased FEV1 after the first dose with an improvement of 93 ml within 5 minutes and 144 ml within 15 minutes of dosing, compared to placebo (both p<0.001).
Croatian: 6-mjesečnom ispitivanju, Enurev Breezhaler je povećao FEV1 nakon prve doze s poboljšanjem od 93 ml u rok od 5 minuta te 144 ml u roku od 15 minuta od primjene doze, u usporedbi s placebom (oba p<0,001).
English: Other medicines and Enurev Breezhaler
Croatian: Drugi lijekovi i Enurev Breezhaler
English: Enurev Breezhaler administered at 44 micrograms once daily statistically significantly reduced breathlessness as evaluated by the Transitional Dyspnoea Index (TDI).
Croatian: Enurev Breezhaler koji se primjenjivao u dozi od 44 mikrograma jedanput na dan statistički značajno je smanjio gubitak daha ocijenjen prema Prijelaznom indeksu dispneje (eng.
English: Enurev Breezhaler 44 micrograms inhalation powder, hard capsules
Croatian: Enurev Breezhaler 44 mikrograma prašak inhalata, tvrde kapsule
English: Instructions for use of Enurev Breezhaler inhaler
Croatian: Upute za primjenu Enurev Breezhaler inhalatora
English: In patients with severe renal impairment (estimated glomerular filtration rate below 30 ml/min/1.73 m2), including those with end-stage renal disease requiring dialysis, Enurev Breezhaler should be used only if the expected benefit outweighs the potential risk (see section 5.2).
Croatian: U bolesnika s teškim oštećenjem bubrega (procijenjena glomerularna filtracija manja od 30 ml/min/1,73 m2), uključujući i one s bolešću bubrega u završnoj fazi koja zahtijeva dijalizu, Enurev Breezhaler treba koristiti samo ako očekivana korist premašuje potencijalni rizik (vidjeti dio 5.2).
English: In patients with severe renal impairment (eGFR <30 ml/min/1.73 m2), including those with end-stage renal disease requiring dialysis, Enurev Breezhaler should only be used if the expected benefit outweighs the potential risk (see section 4.4).
Croatian: U bolesnika s teškim oštećenjem bubrega (eGFR <30 ml/min/1,73 m uključujući one s bolešću bubrega u završnoj fazi koja zahtijeva dijalizu, Enurev Breezhaler treba koristiti samo ako očekivana korist premašuje potencijalni rizik (vidjeti dio 4.4).
English: Your Seebri Breezhaler Inhaler pack contains:
Croatian: Vaše pakiranje Enurev Breezhaler inhalatora sadrži:
English: In a pooled analysis of the first 6 months of treatment in the 6- and 12-month studies, compared to placebo Enurev Breezhaler statistically significantly prolonged time to first moderate or severe exacerbation and reduced the rate of moderate or severe COPD exacerbations (0.53 exacerbations/year versus 0.77exacerbations /year, p<0.001).
Croatian: U objedinjenoj analizi prvih 6 mjeseci liječenja u 6- i 12-mjesečnom ispitivanju, u usporedbi s placebom Enurev Breezhaler statistički značajno je produljio vrijeme do prve umjerene ili teške egzacerbacije i smanjio stopu umjerenih ili teških egzacerbacija KOPB-a (0,53 egzacerbacija na godinu u usporedbi s 0,77 egzacerbacija na godinu, p<0,001).
English: At 12 weeks (primary endpoint), Enurev Breezhaler increased trough FEV1 by 108 ml in the 6-month study and by 97 ml in the 12-month study compared to placebo (both p<0.001).
Croatian: Nakon 12 tjedana (primarna mjera ishoda), Enurev Breezhaler je povećao najniži FEV1 za 108 ml u 6-mjesečnom ispitivanju te za 97 ml u 12-mjesečnom ispitivanju u usporedbi s placebom (oba p<0,001).
English: The capsules must only be removed immediately before use.
Croatian: Kapsule se morajuizvaditi neposredno prije primjene.
English: Enurev Breezhaler can be used at the recommended dose in patients with mild to moderate renal impairment.
Croatian: Enurev Breezhaler se može koristiti u preporučenoj dozi u bolesnika s blagim do umjerenim oštećenjem bubrega.
English: Patients with hepatic impairment Clinical studies have not been conducted in patients with hepatic impairment.
Croatian: Klinička ispitivanja nisu se provodila u bolesnika s oštećenjem jetre.
English: Enurev Breezhaler was found to decrease dyspnoea and leg discomfort when exercising as measured using Borg scales.
Croatian: Uočeno je da Enurev Breezhaler smanjuje dispneju i nelagodu u nogama kod fizičke aktivnosti mjereno korištenjem Borgove skale.
English: Enurev Breezhaler 44 micrograms inhalation powder, hard capsules glycopyrronium (as glycopyrronium bromide)
Croatian: Enurev Breezhaler 44 mikrograma prašak inhalata, tvrde kapsule glikopironij (glikopironijev bromid)
English: In a pooled analysis of the 6and 12-month pivotal studies a statistically significantly higher percentage of patients receiving Enurev Breezhaler responded with a 1 point or greater improvement in the TDI focal score at week 26 compared to placebo (58.4% and 46.4% respectively, p<0.001).
Croatian: U objedinjenoj analizi 6- i 12-mjesečnih ključnih ispitivanja statistički značajno viši postotak bolesnika koji su primali Enurev Breezhaler odgovorio je s poboljšanjem od 1 boda ili većim u TDI-u u 26. tjednu u usporedbi s placebom (58,4% odnosno 46,4%, p<0,001).
English: A pooled analysis of the 6- and 12-month pivotal studies found a statistically significantly higher percentage of patients receiving Enurev Breezhaler responded with a 4 point or greater improvement in SGRQ compared to placebo at week 26 (57.8% and 47.6% respectively, p<0.001).
Croatian: Objedinjenom analizom 6- i 12-mjesečnih ključnih ispitivanja uočen je u bolesnika koji su primali Enurev Breezhaler statistički značajno viši postotak bolesnika koji su odgovorili s poboljšanjem od 4 boda ili više u SGRQ-u u usporedbi s placebom nakon 26 tjedana (57,8% odnosno 47,6%, p<0,001).
English: Do not use Enurev Breezhaler - if you are allergic to glycopyrronium bromide or any of the other ingredients of this medicine
Croatian: Što morate znati prije nego počnete primjenjivati Enurev Breezhaler Nemojte primjenjivati Enurev Breezhaler - ako ste alergični na glikopironijev bromid ili neki drugi sastojak ovog lijeka (naveden u dijelu 6.).
English: What Enurev Breezhaler is
Croatian: Što je Enurev Breezhaler
English: Enurev Breezhaler 44 mcg inhalation powder glycopyrronium
Croatian: Enurev Breezhaler 44 µg prašak inhalata glikopironij
English: 2) Reports have been received from post-approval marketing experience in association with the use of Enurev Breezhaler.
Croatian: 1) Učestalije za glikopironij nego za placebo samo u bazi 12-mjesečnih podataka 2) Dobivena su izvješća iz iskustva nakon stavljanja lijeka u promet, povezana s primjenom Enurev Breezhalera.
English: How to use Enurev Breezhaler
Croatian: Kako primjenjivati Enurev Breezhaler
English: How to store Enurev Breezhaler
Croatian: Kako čuvati Enurev Breezhaler
English: What Enurev Breezhaler is used for
Croatian: Za što se koristi Enurev Breezhaler
English: Immediate hypersensitivity reactions have been reported after administration of Enurev Breezhaler.
Croatian: Nakon primjene Enurev Breezhalera zabilježene su neposredne reakcije preosjetljivosti.
English: Dysuria
Croatian: Mučnina
English: The dose is 3 capsules per day, taken together at the same time each day.
Croatian: Doza je tri kapsule dnevno, koje se uzimaju zajedno i u isto vrijeme svakog dana.
English: Zejula is available as capsules (100 mg) to be taken by mouth.
Croatian: Lijek Zejula dostupan je u obliku kapsula (100 mg) koje se uzimaju kroz usta.
English: The most common side effects with Zejula (which may affect more than 1 in 10 people) are nausea (feeling sick), thrombocytopenia (low blood platelet counts), tiredness and weakness, anaemia (low red blood cell counts), constipation, vomiting, abdominal (belly) pain, neutropenia (low levels of neutrophils, a type of white blood cell), insomnia (difficulty sleeping), headache, lack of appetite, nasopharyngitis (inflammation of the nose and throat), diarrhoea, dyspnoea (difficulty breathing), hypertension (high blood pressure), dyspepsia (heartburn), back pain, dizziness, cough, urinary tract infection (infection of the structures that carry urine), joint pain, palpitations and dysgeusia (taste disturbances).
Croatian: Najčešće nuspojave lijeka Zejula (koje se mogu javiti u više od 1 na 10 osoba) jesu mučnina (slabost), trombocitopenija (nizak broj krvnih pločica), umor i osjećaj slabosti, anemija (nizak broj crvenih krvnih stanica), zatvor, povraćanje, abdominalna bol (bol u trbuhu), neutropenija (nizak broj neutrofila, vrste bijelih krvnih stanica), nesanica (teškoće pri spavanju), glavobolja, smanjen apetit, nazofaringitis (upala nosa i grla), proljev, dispneja (otežano disanje), hipertenzija (visok krvni tlak), dispepsija (žgaravica), bol u leđima, omaglica, kašalj, infekcija mokraćnog sustava (infekcija struktura koje prenose urin), bol u zglobovima, palpitacije i disgeuzija (poremećaj okusa).
English: Other information about Zejula
Croatian: Ostale informacije o lijeku Zejula
English: What measures are being taken to ensure the safe and effective use of Zejula?
Croatian: Koje se mjere poduzimaju kako bi se osigurala sigurna i učinkovita primjena lijeka Zejula?
English: What is Zejula and what is it used for?
Croatian: Što je Zejula i za što se koristi?
English: By blocking PARP enzymes, the damaged DNA in cancer cells cannot be repaired, and, as a result, the cancer cells die.
Croatian: Blokiranjem enzima PARP oštećeni DNK u stanicama raka ne može se popraviti i, posljedično, stanice raka umiru.
English: The medicine can only be obtained with a prescription and treatment should be started and supervised by a doctor who has experience in the use of cancer medicines.
Croatian: Lijek se izdaje samo na recept, a liječenje treba započeti i nadzirati liječnik s iskustvom u primjeni lijekova protiv raka.
English: This is a summary of the European public assessment report (EPAR) for Zejula.
Croatian: Ovo je sažetak europskoga javnog izvješća o procjeni (EPAR) lijeka Zejula.
English: Serious side effects include thrombocytopenia and anaemia.
Croatian: Ozbiljne nuspojave uključuju trombocitopeniju i anemiju.
English: It is not intended to provide practical advice on how to use Zejula.
Croatian: Svrha sažetka nije davati praktične savjete o primjeni lijeka Zejula.
English: Treatment should continue until the disease gets worse.
Croatian: Liječenje treba trajati do progresije bolesti.
English: The active substance in Zejula, niraparib, blocks the action of enzymes called PARP-1 and PARP-2, which help to repair damaged DNA in cells when the cells divide to make new cells.
Croatian: Djelatna tvar lijeka Zejula, niraparib, blokira djelovanje enzima PARP-1 i PARP-2, koji pomažu popraviti oštećeni DNK u stanicama kad se stanice dijele kako bi nastale nove stanice.
English: The medicine is given after treatment with platinumbased medicines, when the tumour is diminishing in size or has completely disappeared.
Croatian: Lijek se daje nakon liječenja lijekovima koji sadržavaju platinu, kad se tumor smanji ili u cijelosti nestane.
English: Why is Zejula approved?
Croatian: Zašto je lijek Zejula odobren?
English: What are the risks associated with Zejula?
Croatian: Koji su rizici povezani s lijekom Zejula?
English: Because the number of patients with ovarian cancer is low, the disease is considered ‘rare', and Zejula was designated an ‘orphan medicine' (a medicine used in rare diseases) on 4 August 2010.
Croatian: Budući da je broj bolesnika s rakom jajnika nizak, dotična se bolest smatra „rijetkom” te je lijek Zejula dobio status „lijeka za rijetku bolest” 4. kolovoza 2010.
English: The European Medicines Agency therefore decided that Zejula's benefits are greater than its risks and recommended that it be approved for use in the EU.
Croatian: Stoga je Europska agencija za lijekove odlučila da koristi lijeka Zejula nadmašuju s njim povezane rizike te je preporučila njegovo odobrenje za primjenu u Europskoj uniji.
English: Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Zejula have been included in the summary of product characteristics and the package leaflet.
Croatian: Preporuke i mjere opreza kojih se zdravstveni radnici i bolesnici trebaju pridržavati u cilju sigurne i učinkovite primjene lijeka Zejula nalaze se u sažetku opisa svojstava lijeka i u uputi o lijeku.
English: This may allow the next cycle of platinum-based therapy to be delayed.
Croatian: To može omogućiti odgodu sljedećeg ciklusa terapije koja sadržava platinu.
English: Patients treated with Zejula lived on average 11.3 months without their disease getting worse compared with 4.7 months in patients treated with placebo (a dummy treatment).
Croatian: Bolesnici koji su liječeni lijekom Zejula živjeli su u prosjeku 11,3 mjeseca bez pogoršanja bolesti, u usporedbi s 4,7 mjeseci u bolesnika koji su primali placebo (prividno liječenje).
English: The summary of the opinion of the Committee for Orphan Medicinal Products for Zejula can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/Rare disease designation.
Croatian: Sažetak mišljenja Odbora za lijekove za rijetke bolesti o lijeku Zejula možete naći na internetskim stranicama Agencije: ema.europa.eu/Find medicine/Human medicines/Rare disease designation.
English: Treatment may be interrupted and the dose may be reduced in patients who experience side effects.
Croatian: Liječenje se može prekinuti i doza se može smanjiti u bolesnika kod kojih nastupe nuspojave.
English: Although treatments for advanced, relapsed ovarian cancer are available, the disease inevitably comes back again.
Croatian: Unatoč dostupnosti liječenja uznapredovaloga karcinoma jajnika u relapsu, bolest se neizbježno vraća.
English: Zejula contains the active substance niraparib.
Croatian: Lijek Zejula sadržava djelatnu tvar niraparib.
English: Regarding safety, side effects are generally manageable with dose reductions.
Croatian: Kad je riječ o sigurnosti, nuspojave se uglavnom mogu kontrolirati smanjenjem doze.
English: Patients had undergone treatment with two or more platinum-based therapies, with a lasting response (the cancer had not progressed for at least 6 months) before the last platinum-based therapy.
Croatian: Bolesnici su podvrgnuti liječenju koje obuhvaća dvije ili više terapija koje sadržavaju platinu, s dugotrajnim pozitivnim rezultatom (karcinom se nije pogoršao najmanje šest mjeseci) prije posljednje terapije koja sadržava platinu.
English: For more information about treatment with Zejula, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Croatian: Više informacija o liječenju lijekom Zejula pročitajte u uputi o lijeku (također dio EPAR-a), odnosno obratite se svojem liječniku ili ljekarniku.
English: The full EPAR for Zejula can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Croatian: Cjelovito europsko javno izvješće o ocjeni procjeni (EPAR) lijeka Zejula nalazi se na internetskim stranicama Agencije: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: Zejula has been shown to prolong the time before the disease gets worse again in patients who have responded to platinum-based therapies.
Croatian: Utvrđeno je da lijek Zejula produljuje vrijeme prije ponovnog pogoršanja bolesti u bolesnika koji su odgovorili na terapiju koja sadržava platinu.
English: Zejula is a cancer medicine used in adult women with a type of advanced cancer of the ovary called ‘high grade serous epithelial ovarian cancer', including cancer of the fallopian tubes (the tubes connecting the ovaries to the uterus) and cancer of the peritoneum (the membrane lining the abdomen).
Croatian: Zejula je lijek protiv raka koji se primjenjuje u odraslih žena s uznapredovalim rakom jajnika koji se zove „serozni epitelijalni karcinom jajnika visokog stupnja”, uključujući rak jajovoda (cjevasti organi koji povezuju jajnike s maternicom) i rak peritoneuma (opna koja obavija organe u trbušnoj šupljini).
English: Patients in the study had high grade serous epithelial ovarian cancer, including fallopian tube or peritoneal cancers.
Croatian: Bolesnici koji su sudjelovali u ispitivanju imali su serozni epitelijalni karcinom jajnika visokog stupnja, uključujući rak jajovoda ili rak peritoneuma.
English: Zejula is used on its own for the ‘maintenance' treatment of patients who have relapsed disease (when the cancer comes back after previous treatment).
Croatian: Zejula se primjenjuje u monoterapiji kao terapija „održavanja” u bolesnika s relapsom bolesti (kad se karcinom vrati nakon prethodnog liječenja).
English: For practical information about using Zejula, patients should read the package leaflet or contact their doctor or pharmacist.
Croatian: Praktične informacije o primjeni lijeka Zejula bolesnici trebaju pročitati u uputi o lijeku, odnosno obratiti se svojem liječniku ili ljekarniku.
English: What benefits of Zejula have been shown in studies?
Croatian: Koje su koristi lijeka Zejula utvrđene u ispitivanjima?
English: How does Zejula work?
Croatian: Kako djeluje Zejula?
English: How is Zejula used?
Croatian: Kako se Zejula koristi?
English: Zejula must not be used in women who are breastfeeding.
Croatian: Lijek Zejula ne smiju uzimati dojilje.
English: For the full list of all side effects reported with Zejula, see the package leaflet.
Croatian: Potpuni popis nuspojava zabilježenih pri primjeni lijeka Zejula potražite u uputi o lijeku.
English: Zejula has been shown to increase the time patients lived without their disease getting worse in one main study involving 553 patients.
Croatian: U glavnom ispitivanju u kojemu su sudjelovala 533 bolesnika utvrđeno je da lijek Zejula povećava vrijeme bez pogoršanja bolesti.
English: Long-term safety in MRCC
Croatian: Dugoročna sigurnost u MRCC
English: You may require medical attention.
Croatian: Možda će Vam trebati medicinska pomoć.
English: e Median not achieved because the data were not yet mature.
Croatian: e Medijan nije postignut jer podaci još nisu bili zreli.
English: None of the subjects achieved complete response or partial response.
Croatian: Nijedan od ispitanika nije postigao potpuni odgovor ili djelomični odgovor.
English: Sutent with food and drink
Croatian: Sutent s hranom i pićem
English: What Sutent is and what it is used for
Croatian: Što je Sutent i za što se koristi
English: Sutent is not recommended for people aged under 18.
Croatian: Sutent se ne preporučuje osobama mlađima od 18 godina.
English: No significant differences in safety or efficacy were observed between younger and older patients.
Croatian: Nisu opažene značajne razlike u sigurnosti ili djelotvornosti između mlađih i starijih bolesnika.
English: • Abnormally decreased/increased sensitivity, particularly to touch.
Croatian: • Neuobičajeno smanjena/povećana osjetljivost, osobito na dodir.
English: The patient should take the usual prescribed dose on the following day.
Croatian: Bolesnik treba uzeti uobičajenu propisanu dozu sljedećeg dana.
English: If you have accidentally taken too many capsules, talk to your doctor straight away.
Croatian: Ako ste slučajno uzeli previše kapsula, odmah se obratite svom liječniku.
English: Tell your doctor or pharmacist if you are taking, have recently taken, or might take any other medicines, including medicines obtained without a prescription and even those not prescribed.
Croatian: Obavijestite svog liječnika ili ljekarnika ako uzimate, nedavno ste uzeli ili biste mogli uzeti bilo koje druge lijekove, uključujući i one koje ste nabavili bez recepta, uključujući i one koji Vam nisu propisani.
English: Talk to your doctor before taking Sutent:
Croatian: Obratite se svom liječniku prije nego uzmete Sutent: